Oncology

A new clinical trial is testing a device that uses electricity to deliver chemo directly into tumors, a strategy that could revolutionize treatment.

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

The 12th Annual Ride of Hope adds new challenging routes to honor Terry's legacy, channeling funds into cutting-edge precision cancer research.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Renowned cancer researcher Dr. Dario Altieri leaves a top CEO post to return to the lab at Jefferson, signaling a major shift in Philadelphia's science scene.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

Europe's top cancer center adopts an AI orchestration platform, aiming to cut wait times, boost efficiency, and reshape the patient journey.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Mestag Therapeutics begins a human trial for MST-0312, a novel antibody designed to force tumors to build their own immune-boosting structures.

A $200,000 donation, part of a $1M commitment, funds vital cancer research and celebrates one young girl's triumphant journey to recovery.

With 10 partner-owned drugs in clinics, MindWalk leverages its decades of wet-lab success to prove its new AI platform is more than just hype.

Biotheryx's novel protein degrader, BTX-9341, shows impressive safety and efficacy in patients who have progressed on standard therapies.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

The biotech firm raises cash via a complex warrant deal, diluting shares to fund its promising but challenging RNAi therapy for deadly KRAS-driven cancers.

The Nexus Forum launches to connect China's booming biotech scene with global pharma, capitalizing on a major shift in worldwide drug discovery and deal-making.

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

With strong HIFU revenue and new clinical trials, EDAP TMS's upcoming Investor Day will reveal its strategy for medtech dominance and investor confidence.

University of Michigan Health is the first in the Midwest to use Unfold AI, a new platform creating 3D cancer maps to personalize patient treatment.

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.